| abstract |
FIELD: medicine. ^ SUBSTANCE: there is offered adrenocorticotropic hormone (ACTH) analogue consisting of 24 amino acid residues and representing a S-truncated natural human peptide (hACTH 1-24) wherein the sequence Lys15-Lys16-Arg17-Arg18-Pro19 is replaced by the sequence Lys15-Arg16-Ala17-Ala18-Trp19. A new mutant ACTH-form shows such properties, as (1) reduced corticosteroid secretion by the adrenal membrane with the ACTH analogue added, as compared with modified ACTH; (2) reduced corticosteroid secretion by the adrenal membrane with endogenic ACTH added, and (3) higher MC-2R fixation affinity with lower MC-2R receptor activation as compared with a version of non-modified ACTH fixation. ^ EFFECT: whole set of properties characterising ACTH analogue under the invention, allows to use it as directly, and in a pharmaceutical composition for treating ACTN-associated conditions, particularly in Cushing disease. ^ 11 cl, 5 dwg, 5 tbl, 5 ex |